Vote Scores
Filings read through

How funds voted at Nektar Therapeutics

Ticker
NKTR
SEC company number
906709
Filers reporting
240, year to 30 June 2026
Latest meeting on file
Meetings on file
3

In the year to 30 June 2026, 240 filers on Form N-PX reported votes at Nektar Therapeutics. The votes fall in one meeting. The figures count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting. Filers gave 386 marks to the ballot items, each with or against management. 95.3% of the marks are with management.

On say-on-pay, 9 of the 221 reporting filers that marked the item voted against management. This is 4.1% of the filers. Of the reported shares, 0.2% went against management. The median of the 3,799 companies on this site with a say-on-pay item is 6.6% of filers and 2.9% of reported shares.

At the meeting of 4 Jun 2026, 29 fund families have a say-on-pay position with management and 1 has a position against management.

By filers reporting in the year to 30 June 2026, Nektar Therapeutics was number 2,295 of 11,972 companies with a page and votes in that year. The number of filers reporting at Nektar Therapeutics rose by 28.3% from the year to 30 June 2025 to the year to 30 June 2026. At the companies on this site with filers in both years, the total of filers reporting rose by 6.0%. In all seasons on file, category DIRECTOR ELECTIONS is 23.0% of the vote records at Nektar Therapeutics. At all companies on this site, it is 52.2%.

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

Since the last update

The site has recorded no change in the tracked figures of this page.

Tracked: the meetings on file and the date of the latest meeting. All recorded changes

The ballot of 4 Jun 2026

238 filers reported votes at this meeting in the year to 30 June 2026. The items are in ballot order: the company's items first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting. The meeting page has the split by reported shares and a CSV file.

  1. Item 1: Director elections

    1 nominee. 83.7% of the reported votes are for. 7 filers withheld from or voted against at least one nominee.

    87 vote records from 54 filers. 4 of the 54 filers that marked the item voted against management.

    • Positions of 23 fund families
    • For 21
    • Against 2
    • Against management 2
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    307 vote records from 237 filers. 9 of the 221 filers that marked the item voted against management. 16 filers gave no management mark.

    • Positions of 30 fund families
    • For 29
    • Against 1
    • Against management 1
  3. Item 3: Audit-related items (auditor ratification)

    87 vote records from 54 filers. 1 of the 54 filers that marked the item voted against management.

    • Positions of 23 fund families
    • For 23
  4. Item 4: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    94 vote records from 57 filers. 4 of the 57 filers that marked the item voted against management.

    • Positions of 23 fund families
    • For 21
    • Against 2
    • Against management 2

Positions of the fund families at the meeting of 4 Jun 2026

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Nektar Therapeutics, meeting of 4 Jun 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund familySay-on-pay
AllspringFor
American CenturyAgainst, against management
BlackRock and iSharesFor
BNY MellonFor
Charles SchwabFor
Columbia ThreadneedleFor
DWSFor
EquitableFor
FidelityFor
Goldman SachsFor
Guggenheim and RydexFor
InvescoFor
John Hancock and ManulifeFor
Lord AbbettFor
Macquarie and Delaware FundsFor
MassMutualFor
Morgan Stanley, Eaton Vance and CalvertFor
Natixis and Loomis SaylesFor
Neuberger BermanFor
Northern Trust and FlexSharesFor
Nuveen and TIAAFor
PGIM and PrudentialFor
PrincipalFor
ProShares and ProFundsFor
Russell InvestmentsFor
SEIFor
State Street and SPDRFor
T. Rowe PriceFor
VanguardFor
Victory CapitalFor

Every meeting on file

Meetings of Nektar Therapeutics, from Form N-PX filings, newest firstA meeting with 20 or more reporting filers has its own page. Dates up to three days apart count as one meeting.
MeetingSeasonFilers reportingItemsFilers against management on say-on-pay
year to 30 June 202623844.1%
year to 30 June 202518657.3%
year to 30 June 202415343.5%

Say-on-pay, season by season

Say-on-pay at Nektar Therapeutics: filers reporting on Form N-PXThe share of filers, and of the shares they reported, that voted against management.
SeasonFilers reportingFilers against managementReported shares against management
year to 30 June 20262404.1%0.2%
year to 30 June 20251877.3%0.6%
year to 30 June 20241533.5%6.5%
Nektar Therapeutics and the median of companies on this site, year to 30 June 2026
Say-on-payThis companyMedian of companies on this site
Filers against management4.1%6.6%
Reported shares against management0.2%2.9%

The median covers 3,799 companies. Each has a say-on-pay item that 20 or more filers reported. The two figures are not a grade. The median is a reference only.

Vote records at Nektar Therapeutics by category, every seasonThe category is the one each filer chose.
CategoryVote recordsShare
DIRECTOR ELECTIONS42123.0%
SECTION 14A SAY-ON-PAY VOTES72939.9%
AUDIT-RELATED23212.7%
CAPITAL STRUCTURE20211.1%
COMPENSATION24313.3%

The record at the SEC

Each link loaded on .

Embed this card on your site

Copy this code into your page. The card shows the figures above with their source. A line under the card links to this page.

How embedding works. It is free. Keep the link in the card and the link line under it.

Cite this page

Vote Scores. How funds voted at Nektar Therapeutics. https://votescores.com/company/nektar-therapeutics/. Source: SEC EDGAR, Form N-PX and N-PX/A filings read through .

Questions

How many meetings of Nektar Therapeutics are on file?
3 meetings are on file, from 5 Jun 2024 to 4 Jun 2026. 3 meetings have 20 or more reporting filers and have their own page.
Did filers report proposals from security holders at Nektar Therapeutics?
Not enough filers reported a proposal from security holders for the site to show one in the year to 30 June 2026. The ballot shows the items that filers did report.
Is this the meeting result?
No. The figures count the filers that report on Form N-PX and the shares they reported. Other holders are not in the count. Nektar Therapeutics reports the result of a vote on Form 8-K.
How does the site group meetings and names?
Filers type company names and meeting dates themselves. The site groups spellings of one company name. It treats meeting dates up to three days apart as one meeting. The data runs through 13 Nov 2026.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Nektar Therapeutics, grouped by company. The name is the most common spelling among filers. The ticker and the SEC company number come from the SEC company tickers file, matched on the exact name. The filers wrote the filings. Filings read through .